Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic - 2At least 36 dead in major fire in Hong Kong residential blocks
- 3CPA Canada appoints eight directors as new governance model takes effect
- 423 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- 5The Response Uncovered: Disentangling the Secrets of the Universe
- Israel, Gulf states report fresh missile and drone attacks
- Getting Your Youngsters' Future: Grasping Legacy Regulations
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Extraordinary Shows to Long distance race on a Plane
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- These 45 exoplanets may be the best places to search for alien life
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
